LIXTE Receives U.S. Patent Issue Notification for Immune Oncology Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their cancers (loss-of-function mutations) correlates...